Q-omics provides the consensus-scored BARX2 profile across patient tissues and cancer cell-line models. BARX2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BARX2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BARX2 RNA expression shows 12,949 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where BARX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BARX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BARX2 survival associations across molecular data types. BARX2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BARX2 RNA expression–survival associations across cancer types. High BARX2 expression shows unfavorable associations in UCEC, UVM, BLCA, PAAD and ACC, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for BARX2 RNA expression.
This table summarizes BARX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BARX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BARX2 shows lower tumor expression in HNSC, THCA and COAD and higher tumor expression in KIRC, LUAD and LUSC. The KIRC box plot shows higher BARX2 RNA expression in tumor versus normal tissue (log2 FC = +2.972, t-test p < 0.001).
This table shows molecular features associated with BARX2 in patient tissues and cancer cell lines. In patient samples, BARX2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BARX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OVARY.
